All News CureVac N.V.

Equities

CVAC

NL0015436031

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
2.33 ^USD	+0.87%		-4.51%	-44.66%

04-26	UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	MT
04-25	Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	04-26	MT
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza Development in Collaboration with GSK	04-25	AQ
Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4	04-25	MT
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
CureVac Begins Early Stage Portion of Investigational Vaccine Trial	04-24	MT
CureVac Hires New Chief Business Officer	04-24	MT
CureVac, GSK Launch Phase 1/2 Trial of Bird Flu Vaccine Candidate	04-24	MT
Transcript : CureVac N.V., Q4 2023 Earnings Call, Apr 24, 2024	04-24
Earnings Flash (CVAC) CUREVAC Posts Q4 Revenue EUR22.6M	04-24	MT
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024	04-24	CI
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza; Development in Collaboration with GSK	04-24	CI
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update	04-24	EQ
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK	04-24	EQ
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer	04-24	EQ
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024	04-18	EQ
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines	04-17	AQ
CureVac N.V. and the University of Texas MD Anderson Cancer Center Enter Strategic Collaboration to Develop Novel Cancer Vaccines	04-16	CI
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines	04-16	EQ
CureVac Says Phase 2 Interim Data Show Multivalent Flu Vaccine Candidate Boosts Antibody Titers	04-04	MT
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study	04-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

CUREVAC : An untrimmed pipeline becomes costly

November 29, 2023 at 02:56 am